期刊文献+

基因工程菌生物合成叔亮氨酸的条件研究 被引量:6

Research on Conditions of L-Tert-Leucine Biosynthesis by Genetically Engineered Escherichia Coli
原文传递
导出
摘要 研究酶法合成叔亮氨酸的反应条件。利用产亮氨酸脱氢酶基因工程菌和产甲酸脱氢酶基因工程菌进行混合全细胞生物转化反应合成叔亮氨酸,考察了诱导剂IPTG浓度、诱导温度和诱导时间等不同诱导条件对产亮氨酸脱氢酶基因工程菌和产甲酸脱氢酶基因工程菌产酶比活力的影响,确定了两种基因工程菌优化的诱导表达条件;通过单因子试验(如转化pH值、转化温度、底物浓度和菌体浓度等)来研究不同反应条件对基因工程菌催化合成叔亮氨酸的影响。结果:工程菌催化合成叔亮氨酸的最适pH是9.5,适合的反应温度为30℃,且两种重组菌的反应湿重比为2∶1时,可达到最高的产量。较高的底物浓度会对反应产生抑制作用,适当提高菌体浓度可以降低底物的抑制作用。通过采用底物分批流加的添加方法,得到了更好的转化效果,最后可达到叔亮氨酸产量为42 mg/ml。 To study the transformation condition of L - tert- Leucine by E. coli. the genetic engineering Genetically engineered E. coli produced leucine dehydrogenase and fomate dehydrogenase which were used to biosynthesine L - tert - Leucine, and the substrate was trimethypyruvic acid. The biosynthesis conditions were investigated to obtain the highest product yield. The usual factors such as the optimum IPTG concentration, the inductive temperature and inductive time of the genetically engineered E. coli were determined. Factorial experiment design was employed to determine the effects of the reactive conditions (such as pH value, substrate concentration, and reactive temperature) on L-tert-Leucine biosynthesis. The results showed that pH9. 5 and 30℃ were the optimum conditions for L-tert-Leucine biosynthesis. L-tert-Leucine biosynthesis was inhibited by the high substrate concentration but it also was manifested that high density of recombinant cells can decrease this inhibitory effect.
作者 黎舒婷 王旻
出处 《药物生物技术》 CAS CSCD 2009年第3期202-206,共5页 Pharmaceutical Biotechnology
关键词 叔亮氨酸 基因工程菌 诱导表达 生物合成 L-tert-Leucine, Genetically engineered bacteria, Expression, Biosynthesis
  • 相关文献

参考文献5

二级参考文献93

  • 1吕陈秋,姜忠义,王姣.烟酰型辅酶NAD(P)^+和NAD(P)H再生的研究进展[J].有机化学,2004,24(11):1366-1379. 被引量:20
  • 2张翀,邢新会.辅酶再生体系的研究进展[J].生物工程学报,2004,20(6):811-816. 被引量:21
  • 3许建和,杨立荣,孙志浩,徐岩.迅速发展中的不对称生物催化技术[J].生物加工过程,2005,3(3):1-6. 被引量:16
  • 4陈书霞,王晓武,房玉林.单菌落PCR法直接快速鉴定重组克隆[J].微生物学通报,2006,33(3):52-56. 被引量:34
  • 5刘景晶,李晶,吴梧桐,胡梅清.大肠杆菌L-天门冬酰胺酶Ⅱ基因的高效表达[J].中国药科大学学报,1996,27(11):696-700. 被引量:19
  • 6张树政 伦世仪 等.酶制剂工业[M].北京:科学出版社,1989.709.
  • 7天津生化制药厂 等.抗癌药物-L-门冬酰胺酶[J].医药工业,1974,4:8-8.
  • 8[1]Bommarius A S,Schwarm M,Stingl K,Kottenhahn M,Huthmacher K,Drauz k.Synthesis and Use of Enantiomerically Pure tert-Leucine[J]. Tetrahedron Asym metry,1995,6(12):2851~2888.
  • 9[2]a) Hon S W,Li C H,Kuo J H,Barhate N B,Liu Y H,Wang Y,Chen C T.Catalytic a symmertric coupling of 2-naphthols by chiral tridentate oxavanadium(IV) complexes[J]. Org. Lett., 2001,3(6), 869~872; b) Hoshino Y, Yamamoto H. J. Novel α-a mino acid-based hydroxamic acid ligands for vanadium-catalyzed asymmetric epoxid ation of alylic alcohols[J]. J.Am.Chem. Soc.2000,122(42):10452~10453; c) Imai Y, Zhang W B, Kida T, Nakatsuji Y, Ikeda I. Novel chiral bisoxazoline ligands with a biphenyl backbone: preparation, complexation, and applicatipn in asymmetric catalytic reactions[J]. J. Org. Chem., 2000, 65(11): 3326-3333; d)Saitoh A, Achiwa K, Tamaka K, Morimoto T. Versatile chiral bidentate ligend formα-amino acid: synthetic application and mechanistic consideration in the palladium-medrated asymmetric alylic substitutions[J]. J. Org. Chem., 2000,65(14): 4227~4240.
  • 10[3]a) Xu Z M,Sigh J,Schwinden M D,Zheng B,Kissick T P,Patel B,Humora M J,Quiroz F,Dong Z,Hsieh D M,Heikes J E,Pudipeddi M,Lindrud M D,Srirastava S K,Kronent hal D R,Mueller D R.Process research and development for an efficient synthesis of the HIV protase inhibitor BMS-232632[J].Org.Proc.Res.& Dev.2002,6(3): 323 ~328;b) Benderb S L,Abreo M A.U.S.Metalloproteinase inhibitors,pharmaceutical compositions containing them and their pharmaceutical uses[P].US 5 985 900,1999;c) Prasad J V N V,Loo J A,Boyor F E,Stier M A,Gogliotti R D,Turner W J,Harvey P J,Kramer M R,Mack D P,Scholten J D,Gracheck S J,Domagala J M.2,2-Dithiobibenzam ides derived from α,β-and γ-aminoacid processing anti-HIV activities:synthes is and structure-activity relationship.Bioorg[J].Med.Chem.1998,6(10):1707~1730.

共引文献47

同被引文献125

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部